Bortniker, Lacktman Comment on Novel Teledermatology Program in Massachusetts
November 20, 2017
mHealth Intelligence
Partner Nate Lacktman and Senior Counsel Alexis Finkelberg Bortniker were quoted in a mHealth Intelligence article, “Telemedicine Success Often Hinges on Aligning Providers and Payers,” about the launch of a teledermatology program at 22 remote sites in Massachusetts.
Bortniker said the best way to establish such a program is to approach individual health plans and look for partnerships. “You have to be out there, and you have to find the right payer,” she said. “You have to do your homework and be prepared to convince them.”
Lacktman cited other deliberate efforts by providers to align with payers and embrace cooperation on coverage and reimbursement. “Too many sit back on their heels and say, ‘We’re not getting reimbursed,” he said. “But by communicating with [commercial payers], they have a chance to align their visions.”
Bortniker said the best way to establish such a program is to approach individual health plans and look for partnerships. “You have to be out there, and you have to find the right payer,” she said. “You have to do your homework and be prepared to convince them.”
Lacktman cited other deliberate efforts by providers to align with payers and embrace cooperation on coverage and reimbursement. “Too many sit back on their heels and say, ‘We’re not getting reimbursed,” he said. “But by communicating with [commercial payers], they have a chance to align their visions.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."